Oncothyreon, Sentinel Oncology Agreement Worth Up to $174M

April 23, 2014

Small molecule drug discoverer Sentinel Oncology has made an agreement with Oncothyreon toward developing Sentinel’s Checkpoint Kinase 1 (Chk1) program under which Oncothyreon will fund additional research done at Sentinel toward discovering therapeutics directed at the Chk1 target. The cancer-focused company is also receiving the rights to develop and commercialize any of the compounds that result from Sentinel's research. Sentinel could receive up to $174 million in preclinical, clinical, and commercial milestone payments as part of this agreement, plus any royalties on net sales. Read the full story